HRD in ovarian cancer

1 EU-approved indication in ovarian cancer needs a HRD result: olaparib (maintenance, advanced).

Histology

Line of therapy

Approved indications, Ovarian cancer
DrugBiomarker requirementRegimenSettingConditions
HRD positive1
Olaparib
Lynparza
HRD-positive (BRCA1/2 mutation and/or genomic instability)
+ bevacizumab
Maint.
advanced
High-grade only; In complete or partial response following completion of first-line platinum-based chemotherapy in combination with bevacizumab

8 approvals for Ovarian need no biomarker and apply whatever the result. All approvals for Ovarian

See also

Label wording1

The sentence from section 4.1 of the SmPC that each indication above comes from.

  1. Olaparib (Lynparza)
    maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).